A Argiris1, S Li2, M Ghebremichael3, A M Egloff4, L Wang5, A A Forastiere6, B Burtness7, R Mehra7. 1. Division of Hematology/Oncology Cancer Therapy and Research Center, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio. Electronic address: athanassios.argiris@gmail.com. 2. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston. 3. Ragon Institute of Harvard, MIT and MGH and Harvard Medical School, Boston. 4. Department of Otolaryngology. 5. Department of Pathology, University of Pittsburgh, Pittsburgh. 6. Department of Medical Oncology, Johns Hopkins University, Baltimore. 7. Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA.
Abstract
BACKGROUND: The purpose of this article was to study the association of human papillomavirus (HPV) with clinical outcomes in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). PATIENTS AND METHODS: Archival baseline tumor specimens were obtained from patients treated on two clinical trials in recurrent or metastatic SCCHN: E1395, a phase III trial of cisplatin and paclitaxel versus cisplatin and 5-fluorouracil, and E3301, a phase II trial of irinotecan and docetaxel. HPV DNA was detected by in situ hybridization (ISH) with a wide-spectrum probe. p16 status was evaluated by immunohistochemistry. Clinical outcomes of interest were objective response, progression-free survival (PFS) and overall survival (OS). RESULTS: We analyzed 64 patients for HPV ISH and 65 for p16. Eleven tumors (17%) were HPV+, 12 (18%) were p16+, whereas 52 (80%) were both HPV- and p16-. The objective response rate was 55% for HPV-positive versus 19% for HPV-negative (P = 0.022), and 50% for p16-positive versus 19% for p16-negative (P = 0.057). The median survival was 12.9 versus 6.7 months for HPV-positive versus HPV-negative patients (P = 0.014), and 11.9 versus 6.7 months for p16-positive versus p16-negative patients (P = 0.027). After adjusting for other covariates, hazard ratio for OS was 2.69 (P = 0.048) and 2.17 (P = 0.10), favoring HPV-positive and p16-positive patients, respectively. The other unfavorable risk factor for OS was loss of ≥5% weight in previous 6 months (P = 0.0021 and 0.023 for HPV and p16 models, respectively). CONCLUSION: HPV is a favorable prognostic factor in recurrent or metastatic SCCHN that should be considered in the design of clinical trials in this setting. CLINICAL TRIAL IDENTIFIER: NCT01487733 Clinicaltrials.gov.
BACKGROUND: The purpose of this article was to study the association of human papillomavirus (HPV) with clinical outcomes in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). PATIENTS AND METHODS: Archival baseline tumor specimens were obtained from patients treated on two clinical trials in recurrent or metastatic SCCHN: E1395, a phase III trial of cisplatin and paclitaxel versus cisplatin and 5-fluorouracil, and E3301, a phase II trial of irinotecan and docetaxel. HPV DNA was detected by in situ hybridization (ISH) with a wide-spectrum probe. p16 status was evaluated by immunohistochemistry. Clinical outcomes of interest were objective response, progression-free survival (PFS) and overall survival (OS). RESULTS: We analyzed 64 patients for HPV ISH and 65 for p16. Eleven tumors (17%) were HPV+, 12 (18%) were p16+, whereas 52 (80%) were both HPV- and p16-. The objective response rate was 55% for HPV-positive versus 19% for HPV-negative (P = 0.022), and 50% for p16-positive versus 19% for p16-negative (P = 0.057). The median survival was 12.9 versus 6.7 months for HPV-positive versus HPV-negative patients (P = 0.014), and 11.9 versus 6.7 months for p16-positive versus p16-negative patients (P = 0.027). After adjusting for other covariates, hazard ratio for OS was 2.69 (P = 0.048) and 2.17 (P = 0.10), favoring HPV-positive and p16-positive patients, respectively. The other unfavorable risk factor for OS was loss of ≥5% weight in previous 6 months (P = 0.0021 and 0.023 for HPV and p16 models, respectively). CONCLUSION: HPV is a favorable prognostic factor in recurrent or metastatic SCCHN that should be considered in the design of clinical trials in this setting. CLINICAL TRIAL IDENTIFIER: NCT01487733 Clinicaltrials.gov.
Authors: Nicolas Stransky; Ann Marie Egloff; Aaron D Tward; Aleksandar D Kostic; Kristian Cibulskis; Andrey Sivachenko; Gregory V Kryukov; Michael S Lawrence; Carrie Sougnez; Aaron McKenna; Erica Shefler; Alex H Ramos; Petar Stojanov; Scott L Carter; Douglas Voet; Maria L Cortés; Daniel Auclair; Michael F Berger; Gordon Saksena; Candace Guiducci; Robert C Onofrio; Melissa Parkin; Marjorie Romkes; Joel L Weissfeld; Raja R Seethala; Lin Wang; Claudia Rangel-Escareño; Juan Carlos Fernandez-Lopez; Alfredo Hidalgo-Miranda; Jorge Melendez-Zajgla; Wendy Winckler; Kristin Ardlie; Stacey B Gabriel; Matthew Meyerson; Eric S Lander; Gad Getz; Todd R Golub; Levi A Garraway; Jennifer R Grandis Journal: Science Date: 2011-07-28 Impact factor: 47.728
Authors: Paul M Weinberger; Ziwei Yu; Bruce G Haffty; Diane Kowalski; Malini Harigopal; Janet Brandsma; Clarence Sasaki; John Joe; Robert L Camp; David L Rimm; Amanda Psyrri Journal: J Clin Oncol Date: 2006-01-09 Impact factor: 44.544
Authors: Danny Rischin; Richard J Young; Richard Fisher; Stephen B Fox; Quynh-Thu Le; Lester J Peters; Ben Solomon; Jimin Choi; Brian O'Sullivan; Lizbeth M Kenny; Grant A McArthur Journal: J Clin Oncol Date: 2010-08-09 Impact factor: 44.544
Authors: Carole Fakhry; William H Westra; Sigui Li; Anthony Cmelak; John A Ridge; Harlan Pinto; Arlene Forastiere; Maura L Gillison Journal: J Natl Cancer Inst Date: 2008-02-12 Impact factor: 13.506
Authors: Richard C Jordan; Mark W Lingen; Bayardo Perez-Ordonez; Xin He; Robert Pickard; Michael Koluder; Bo Jiang; Paul Wakely; Weihong Xiao; Maura L Gillison Journal: Am J Surg Pathol Date: 2012-07 Impact factor: 6.394
Authors: T Magnes; T Melchardt; C Hufnagl; L Weiss; C Mittermair; D Neureiter; E Klieser; G Rinnerthaler; S Roesch; A Gaggl; R Greil; A Egle Journal: Pharmacogenomics J Date: 2017-07-18 Impact factor: 3.550
Authors: Glenn J Hanna; Alec Kacew; Nicole G Chau; Priyanka Shivdasani; Jochen H Lorch; Ravindra Uppaluri; Robert I Haddad; Laura E MacConaill Journal: JCI Insight Date: 2018-09-06
Authors: Theresa Guo; Jesse R Qualliotine; Patrick K Ha; Joseph A Califano; Young Kim; John R Saunders; Ray G Blanco; Gypsyamber D'Souza; Zhe Zhang; Christine H Chung; Ana Kiess; Christine G Gourin; Wayne Koch; Jeremy D Richmon; Nishant Agrawal; David W Eisele; Carole Fakhry Journal: Cancer Date: 2015-03-17 Impact factor: 6.860
Authors: Tim N Beck; Chad H Smith; Douglas B Flieder; Thomas J Galloway; John A Ridge; Erica A Golemis; Ranee Mehra Journal: Head Neck Date: 2016-11-08 Impact factor: 3.147
Authors: Alexandre A B A da Costa; Felipe D'Almeida Costa; Daniel Vilarim Araújo; Marcos Pedro Guedes Camandaroba; Victor Hugo Fonseca de Jesus; Audrey Oliveira; Ana Caroline Fonseca Alves; Carlos Stecca; Larissa Machado; Andrea Cruz Feraz de Oliveira; Thiago Bueno de Oliveira; Ulisses Ribaldo Nicolau; Vladmir Cláudio Cordeiro de Lima Journal: Med Oncol Date: 2018-11-26 Impact factor: 3.064
Authors: Eleni M Rettig; Alicia Wentz; Marshall R Posner; Neil D Gross; Robert I Haddad; Maura L Gillison; Carole Fakhry; Harry Quon; Andrew G Sikora; William J Stott; Jochen H Lorch; Christine G Gourin; Yingshi Guo; Weihong Xiao; Brett A Miles; Jeremy D Richmon; Peter E Andersen; Krzysztof J Misiukiewicz; Christine H Chung; Jennifer E Gerber; Shirani D Rajan; Gypsyamber D'Souza Journal: JAMA Oncol Date: 2015-10 Impact factor: 31.777
Authors: Angela L Mazul; Nidia Rodriguez-Ormaza; James M Taylor; Dipan D Desai; Paul Brennan; Devasena Anantharaman; Tarik Gheit; Massimo Tommasino; Behnoush Abedi-Ardekani; Andrew F Olshan; Jose P Zevallos Journal: Oral Oncol Date: 2016-09-06 Impact factor: 5.337